Clinical trial · Interventional
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer
NCT00298688CI-TRIAL-00001535completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gefitinib | Drug | Gefitinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine the disease control rate in these patients
Secondary outcomes (3)
- measure
- To determine the objective response rate at trail closure in these patients
- measure
- To determine the time to progression-or-death in these patients
- measure
- To determine overall survival in these patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provision of written informed consent * Histologically confirmed, relapsed or refractory SCLCr * Aged 18 or over and a life expectancy of more than 2 months Exclusion Criteria: * Any evidence of clinically active interstitial lung disease * Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ.
References
Publications (0)
Data not yet available
No reference posted for this study.